Deep Infiltrating Endometriosis Treatment Today and What May Change

Deep infiltrating endometriosis and the treatment outlook

Deep infiltrating endometriosis extends more than 5 mm beneath a tissue surface, potentially invading organs such as the bowel and bladder. Excision of deep lesions and their associated fibrosis is the best path forward in most suspected or previously diagnosed cases. Medication and supportive care may help symptoms, but they do not eradicate deep disease. A long-standing cure remains out of reach.

Also called deep endometriosis or deep infiltrative endometriosis, this form requires careful assessment of both disease location and its effects on surrounding structures. Surgery is the optimal therapy, followed by supportive care and strategies to reduce recurrence where possible. Molecular approaches may eventually offer more precise diagnosis and treatment, but those targeted therapies remain future possibilities rather than established care.

Symptoms and anatomical patterns

Symptoms and organ involvement

Deep infiltrating endometriosis is relatively uncommon, affecting about 1% of reproductive-age women and roughly 20% of people with endometriosis. Its symptoms resemble those of other forms but are usually more severe. The depth and location of lesions help explain which symptoms occur and which organs may need attention during treatment.

Symptoms can include severe pelvic pain, painful menstruation, and genital pain before, during, or after sex. Urinary involvement may cause painful urination or blood in the urine, while bowel involvement may cause digestive discomfort and rectal bleeding. Disease beyond the pelvis can cause distant symptoms, including pain with breathing when the diaphragm is involved.

How deep lesions differ from superficial lesions and endometriomas

Three major anatomical patterns are recognized in the pelvic and abdominal cavities. Superficial peritoneal endometriosis involves lesions on organ surfaces and generally, though not always, causes the least tissue damage and distortion. Ovarian endometriomas are dark cysts containing old blood, commonly called chocolate cysts, that form in or on the ovaries.

Deep infiltrating endometriosis is the most severe form, penetrating deeply into pelvic organs and causing more extensive damage. Deep lesions and endometriomas are more likely to distort anatomy and cause harm, including pain and reduced fertility. Their molecular characteristics may help explain this behavior, beyond what location alone can tell us.

Diagnosis and surgical mapping

What imaging can and cannot establish

Diagnosis usually draws on medical history, physical examination, ultrasound, MRI, and findings from minimally invasive surgery. Histology, the examination of tissue under a microscope, can confirm the diagnosis after surgery or a biopsy. In an accessible location, such as a C-section scar, a biopsy may provide tissue for evaluation.

A 3-Tesla MRI, often called 3T MRI, is probably the most accurate imaging option. However, it can miss up to 20% of deep disease. MRI helps map disease for surgery, but it should not definitively establish that deep infiltrating endometriosis is present or absent.

If you’d like a second opinion on your imaging or a recommended surgical plan, our team at Lotus Endometriosis Institute can review it.

Why operative findings may change the plan

In many, if not most, cases, the diagnosis becomes apparent and is confirmed only during surgery. The full extent of disease cannot be predicted precisely beforehand, so the findings may change what is needed to remove it.

Imaging-based mapping and close attention to symptoms help the surgical team prepare for comprehensive excision. Choosing a highly skilled, experienced surgeon is prudent, particularly when symptoms are severe. A poorly executed first surgery can complicate subsequent procedures and increase the risk of major complications.

Medical and supportive treatment

Medication and the limits of disease suppression

Medical treatment for deep infiltrating endometriosis is extremely limited and essentially nonexistent in terms of disease eradication. Deep invasion triggers scarring, or fibrosis, as the body tries to wall off and heal the affected area. No known medication eliminates that fibrosis.

Pain relievers and hormonal therapies used for other forms of endometriosis may relieve symptoms and possibly suppress disease. That distinction matters in treatment planning: symptom improvement does not mean that deep lesions and their associated scarring have been removed.

Integrative care and pelvic floor physical therapy

Integrative strategies can help control symptoms, much as they do with other forms of endometriosis. Options include mind-body biofeedback, nutrition, botanicals, essential oils, acupuncture or acupressure, and transcutaneous electrical nerve stimulation, known as TENS. It is best to develop an individualized approach with a qualified practitioner.

Pelvic floor physical therapy is central to treatment planning. Depending on lesion location, internal techniques warrant caution because disrupting deep lesions can potentially make surgery less effective. Coordinated planning between the physical therapist and surgical team is ideal for deciding which techniques to use and when.

Excision and surgical decisions

Why excision matters more than ablation

Excision removes deep lesions and associated fibrosis. It is the preferred path in most cases where deep disease is suspected or has already been diagnosed.

Ablation or fulguration, which destroys tissue rather than cutting it out, is especially unsuitable for lesions of uncertain depth. It is not useful in that setting and carries an elevated risk of injury to nearby structures, including the rectum, bladder, and ureters. The usual emphasis on excision over ablation therefore carries even greater weight in deep disease.

Surgeon experience, robotics, and multidisciplinary preparation

A master surgeon with extensive experience in complex endometriosis is best suited to these procedures. In Dr. Vasilev’s opinion, deep-disease surgery should be performed robotically because the platform provides superior optics and wristed instruments that allow precise work in difficult spaces.

The surgeon should be prepared to address bowel, bladder, and ureteral involvement, including ureteral reimplantation when necessary. Alternatively, the surgeon should work with a well-integrated team ready to participate as planned. Reimplantation reconnects a ureter to the bladder when the affected portion cannot be preserved.

Careful preparation cannot predict every operative requirement, but imaging and symptoms can guide the plan. For a complex case, the team needs the skills and resources to address the organs involved rather than treating only the most visible lesions.

Hysterectomy, ovarian conservation, and fertility

Deep infiltrating endometriosis does not automatically require a hysterectomy. If childbearing is complete, the risks and benefits of removing the uterus may need discussion to ensure that all diseased tissue can be removed. The decision should reflect the location and extent of disease and the person’s goals.

Ovarian conservation is a separate decision that also needs individual consideration. As menopause approaches, or when disease is extensive or cancer risk is higher because of family history or genetic testing, weighing the risks and benefits of keeping the ovaries becomes more prudent.

Deep disease can affect fertility, making surgical technique particularly important. Surgeons should use atraumatic techniques that minimize injury to delicate reproductive structures and improve pregnancy prospects. Dr. Vasilev believes the robotic platform optimizes this goal.

Operative tools and pathology findings

ICG imaging and urinary-tract stents

Indocyanine green fluorescence imaging, or ICG imaging, helps surgeons visualize the ureters. This supports removal of as much infiltrating tissue as possible while protecting the urinary tract. It is also valuable for assessing blood supply and viability in bowel segments that have been operated on, reducing the risk of complications.

During relevant bladder procedures, including partial cystectomy, or removal of part of the bladder, stents can help protect the ureters. These tiny plastic catheters can also enhance healing after ureteral reimplantation.

Pathology findings that may affect follow-up

Beyond routine pathology, additional assessments may be considered for deep disease and ovarian endometriomas, especially when lesions appear clinically aggressive. The pathologist should ensure that there is no clear cell cancer component.

Even when there is no cancer, tissue can be evaluated for its mitotic index, a measure of how many cells are dividing. Increased cell division is more common in aggressive disease. This finding may prompt consideration of well-tolerated hormonal suppression, such as micronized progesterone, to reduce recurrence risk.

Immunohistochemical stains, known as IHC stains, can assess molecular abnormalities associated with gene mutations such as ARID1A. These assessments are not readily available everywhere, but they may be useful when cancer risk is elevated. In the future, abnormal molecular pathways are expected to become targets for precision therapies.

Molecular findings, risk, and future treatments

What molecular differences may explain

The exact cause of deep infiltrating endometriosis remains unknown and is likely multifactorial, making a single explanation unlikely. Family history of endometriosis or cancer matters in this assessment. Molecular findings are moving our understanding beyond anatomy and hormonal factors alone.

Current staging relies largely on anatomical location and the clinical extent of disease. Dr. Vasilev considers this approach old school compared with the potential of molecular diagnostics and precision treatment. Identifying the abnormal pathways driving an individual’s disease may eventually allow treatment to target those pathways directly.

This work extends beyond hormone-receptor activity, hormonal regulation, and relative progesterone resistance. It is too early to classify endometriosis types strictly by gene-mutation pathways, but current knowledge may already help guide efforts to reduce recurrence and cancer risk.

Superficial lesions, ovarian endometriomas, and deep lesions show genetic and molecular heterogeneity, meaning their molecular features vary. Some mutations resemble those found in cancer even when cancer is absent or unlikely to develop. This suggests that endometriosis may represent different disease entities in different people, with varying degrees of aggressiveness.

Within one person, superficial, ovarian, and deep lesions can share clonal molecular signatures, meaning they have related cellular origins. These similarities indicate that one type can progress to another. Mutations of interest include ARID1A, PIK3CA, KRAS, and PPP2R1A, among others.

The effects of these mutations may be suppressed or aggravated by epigenetic influences, which change gene activity. These include diet, lifestyle, toxin exposure, concurrent disease states, and mind-body factors. Such findings are opening diagnostic possibilities and routes toward molecularly guided treatment, rather than providing an established cure now.

Cancer risk and individualized follow-up

Molecular findings suggest that deep disease and ovarian endometriomas may be premalignant conditions, but this remains under investigation and their potential for malignancy is low. Cancer-associated mutations do not mean that cancer is present or will develop. They may instead help explain local invasion, anatomical distortion, pain, reduced fertility, and potentially metastatic behavior, meaning spread to other sites, without cancer.

Ovarian endometriomas carry the highest risk of malignant degeneration among the three anatomical types. ARID1A is considered a key driver mutation for clear cell cancer. Deep disease has a broader range of mutations and a lower risk of malignant degeneration than endometriomas, although those mutations may contribute to more aggressive behavior.

The ovarian microenvironment may be more permissive to malignant change, helping explain the higher risk in endometriomas. That difference does not negate the aggressive, invasive, and potentially spreading behavior of deep disease in the absence of cancer.

A 2025 case report described a 32-year-old woman with low-grade endometrial stromal sarcoma arising from deep infiltrating endometriosis outside the uterus. She underwent extensive cancer surgery and treatment with aromatase inhibitors. This was an exceptionally rare malignant change, not a representative course of deep disease.

With a family history of cancer, genetic testing should be considered. If individual cancer risk is elevated because of family history, genetic findings, or concerning disease features, consultation with a gynecologic oncologist should also be considered. The more complex the situation, the greater the need for an expert endometriosis surgeon and appropriately coordinated specialist input.

Questions to bring to treatment discussions

• Disease mapping: Which organs may be involved, what does my imaging show, and what could it have missed? How might findings during surgery change the plan?
• Treatment goals: Is the proposed treatment intended to relieve symptoms, suppress disease, remove lesions and fibrosis, or reduce recurrence? What can it realistically accomplish?
• Surgical preparation: How much experience does the surgeon have with deep disease, and who will address bowel, bladder, or ureteral involvement if needed? Why is the proposed surgical platform appropriate?
• Fertility and organ preservation: How will surgery protect reproductive structures? What are the reasons for or against hysterectomy and ovarian conservation in my circumstances?
• Supportive care: How should pelvic floor physical therapy and other symptom treatments be coordinated with surgery? Are internal techniques appropriate for my lesion locations?
• Pathology: Will the tissue be assessed for a clear cell cancer component or increased cell division? Would additional molecular or IHC testing affect follow-up or recurrence-reduction options?
• Individual cancer risk: Does my personal or family history warrant genetic testing or a gynecologic oncology consultation? How should my pathology findings affect follow-up?